Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are cutaneous porphyria responsible for a substantial burden on patients, their families, and the healthcare system. To address this burden, important treatment advances, including new classes of medications, continue to be made. In this educational activity, Karl Anderson, MD, discusses preventive and therapeutic options for patients with EPP and XLP, as well as the safety and efficacy of emerging treatments.
0.50 AMA PRA Category 1 CreditsTM
This activity is intended for a national audience of hematologists, hepatologists, gastroenterologists, medical geneticists, dermatologists, advanced care practitioners, primary care physicians, and other healthcare providers who may be involved in diagnosis and treatment of patients with EPP and XLP.
This educational activity is supported by an educational grant from Mitsubishi Tanabe Pharma Development America, Inc.
Accreditation and Certification
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Content PlannersMadison Saxton, PharmD (Medical Writer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
Karl E. Anderson, MD
Galveston Porphyria Laboratory & Center
Professor, Departments of Internal Medicine (Division of Gastroenterology & Hepatology) and Preventive Medicine and Population Health
Director, Clinical Science Graduate Program
Director, Porphyria Laboratory & Center
University of Texas Medical Branch/UTMB Health
- Employ preventive and therapeutic options for patients diagnosed with EPP and XLP that best fit the need of each patient
- Describe the safety and efficacy of emerging treatments for patients with EPP and XLP